Survodutide is another GLP-1/glucagon dual agonist, notable for a research focus
that extends beyond weight management into liver disease.
Chemical identity & structure.
Survodutide is a synthetic peptide dual agonist at the GLP-1 receptor and the
glucagon receptor. Like the other long-acting incretin compounds it is
fatty-acid-modified for albumin binding and an extended half-life.
Mechanism of action.
As with mazdutide, the GLP-1 arm drives appetite, insulin, and gastric-emptying
effects, while the glucagon-receptor arm is hypothesized to increase energy
expenditure and to act on the liver — influencing hepatic fat and metabolism.
The glucagon component is the reason this compound has drawn specific interest
in liver-disease research.
Key research findings.
Survodutide has been studied in clinical trials for weight management and,
notably, for metabolic dysfunction-associated steatohepatitis (MASH) — a
liver condition — where the glucagon-receptor activity is mechanistically
relevant. Published trial data has reported effects on weight and on
liver-related endpoints.
The research / citation base.
Survodutide is an investigational compound in active clinical development;
it is not broadly approved. Its evidence base is genuine clinical-trial
research, including the MASH program. As with the other newer multi-agonists,
the long-term safety profile is still being characterized.
Human clinical trial data
In the 48-week phase 2 trial by Sanyal et al. (2024), adults with biopsy-confirmed MASH and fibrosis stage F1 through F3 were randomly assigned in a 1:1:1:1 ratio to receive survodutide at one of three dose levels or placebo, with a 24-week rapid-dose-escalation phase followed by a 24-week maintenance phase (PubMed).
Quality & sourcing notes.
A batch-specific COA confirming identity by mass spectrometry and HPLC purity is
the minimum bar. Counterfeiting risk is real for any in-demand incretin
compound — verify documentation.
*Research-use note: Educational summary of published research. Survodutide is
investigational; this is research context only and not medical advice.*